FDA
-
-
-
-
-
-
-
Raymond James Downgrades Engene Holdings Inc. (ENGN) to Outperform
-
-
-
-
-
-
-
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
enGene selected for FDA manufacturing pilot program
-
-
-
-
-
-
-
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
-
-
-
-
-
-
-
Engene (ENGN): FDA Grants RMAT Designation for Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
-
-
-
-
-
-
-
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
328,575 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

